Original articleUndifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes
Section snippets
Methods
Institutional review board approval was obtained at all institutions before this study. Electronic medical records, institutional cancer registry data, and pathology databases were used to identify all adult patients who received a diagnosis of UPS, AFX, pleomorphic dermal sarcoma, or MFH from 1980 to 2013 and were evaluated across 3 tertiary medical centers. A retrospective chart and histopathologic review was performed on all confirmed cases on the basis of readout description by a
Clinical predictors
A total of 319 cases of UPS were identified. The median patient age at diagnosis was 72 years (range, 18-94 years), and 259 patients (81.2%) were male. Of the cases, 235 (73.7%) occurred on the head and neck, 20 (6.3%) occurred on the trunk, 22 (6.9%) occurred on an upper extremity, and 34 (10.7%) occurred on an lower extremity (Table I). The median follow-up time was 4.1 years.
Among the subjects studied, 45 (14.1%) developed a local recurrence. The median time to recurrence was 1.2 years
Discussion
Prior studies attempted to characterize cutaneous UPS through differentiation into subtypes of superficial UPS/AFX or deep UPS/MFH with the aid of histopathologic and immunohistochemical assessment.6, 16, 17 However, differentiation based on clinical, histopathologic, or immunohistochemical parameters has been challenging given the limited data available. With the large number of cases in this collective experience, more reliable conclusions are possible. The diagnosis of UPS requires extensive
References (32)
- et al.
Mohs micrographic surgery for the treatment of spindle cell tumors of the skin
J Am Acad Dermatol
(2001) - et al.
Malignant fibrous histiocytoma: changing perceptions and management challenges
J Am Acad Dermatol
(2012) - et al.
Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma
Cancer Genet Cytogenet
(2000) - et al.
Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years
Mod Pathol
(2002) - et al.
H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma
Hum Pathol
(2001) - et al.
Atypical fibroxanthoma: a clinicopathological study of 89 cases
Australas J Dermatol
(2005) - et al.
Atypical fibroxanthoma: a review of the literature
Dermatol Surg
(2011) - et al.
Atypical fibroxanthoma of the skin. A clinicopathologic study of 140 cases
Cancer
(1973) - et al.
Atypical fibroxanthoma of the skin. Presentation of 5 cases and a review of the literature
Br J Dermatol
(1977) - et al.
Atypical fibroxanthoma of the skin: an ultrastructural study of two cases
Cancer
(1977)
The evolving classification of soft tissue tumours—an update based on the new 2013 WHO classification
Histopathology
Atypical fibroxanthoma of the skin with metastasis
Cancer
Metastasizing atypical fibroxanthoma. Coexistence with chronic lymphocytic leukemia
Arch Dermatol
Atypical fibroxanthoma/malignant fibrous histiocytoma
Dermatol Ther
Malignant fibrous histiocytoma: an analysis of 200 cases
Cancer
Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma
Am J Surg Pathol
Cited by (59)
Cooled microwave ablation treatment of locally unresectable undifferentiated pleomorphic sarcoma: A case report
2023, Asian Journal of SurgeryCutaneous Mesenchymal Sarcomas
2023, Dermatologic ClinicsCitation Excerpt :Risk factors for overall mortality mirror those that predispose a patient to metastasis. Older age (>60) patients have poorer survival compared with those in a younger cohort.28 Cutaneous angiosarcoma is a rare, aggressive vascular tumor (incidence rate of 2.25 per 100,000).32
An extremely scarce incidence of primary Undifferentiated Pleomorphic Sarcoma of the Scalp of a 52-year-old female - A Case Report
2022, International Journal of Surgery Case ReportsNeutrophil-to-Lymphocyte ratio as a prognostic biomarker in extremities undifferentiated pleomorphic sarcoma
2022, Surgical OncologyCitation Excerpt :We found that 4.5% in our cohort had LNMD. Presentation with distant metastatic disease occurs in around 7.8% of patients according to a retrospective study by Winchester [20]; our series showed a higher incidence, since 21% presented it. Regarding oncological outcomes, series describing long-term follow up have reported an incidence of local recurrence of 40% and distance metastasis of 25%, with a 5-year OS rate of 53% and a 5-year local recurrence free survival rate of 55% [21,22].
Funding sources: None.
Conflicts of interest: None disclosed.